From Research at med.fsu.edu Fri Oct 28 10:01:26 2022 From: Research at med.fsu.edu (med-Research) Date: Fri, 28 Oct 2022 14:01:26 +0000 Subject: Funding Opportunities Message-ID: NIH Data Management and Sharing (DMS): New Policy for Proposals Submitted after January 25, 2023 The National Institutes of Health (NIH) has issued a new NIH Data Management & Sharing Policy which will go into effect for proposals for NIH funding that are submitted for due dates on or after January 25, 2023. The policy is intended to "promote the management and sharing of scientific data generated from NIH-funded or conducted research" in the interest in part of ensuring improved public access to publicly funded research and enabling data reuse for future studies. FSU COM library staff and FSU library staff are available to advise and assist with meeting the policy requirements, and you may also learn about how the policy may apply to human research via the FSU IRB. NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (Clinical Trial Optional) R34 This Funding Opportunity Announcement (FOA) is a part of NIDA's Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA's research portfolio. The purpose of this FOA is to support pilot or feasibility research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged. R01 This Funding Opportunity Announcement (FOA) is a part of NIDA's Racial Equity Initiative (REI), with goals that include promoting racial equity in NIDA's research portfolio. The purpose of this FOA is to stimulate new observational and intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. Research that addresses the multiple dimensions of individuals' identity (e.g., race, ethnicity, gender, sexual orientation, gender identity) and social systems as they intersect with one another is encouraged. Due November 14, 2022; November 14, 2023; and November 14, 2024. Med-RA deadline to receive draft documents for 2022 due date: October 31 due to Veterans Day holiday. Pfizer Research Grants: 2022/2023 Global COVID-19 ASPIRE The following areas of research will be considered in-scope. 1. Societal impact of COVID-19: Understand the psychological impact, impact on working behaviors, social determinants of health, child development, education, access to healthcare, healthcare resource utilization, direct and indirect costs and impact on QoL 2. Key populations at high-risk of severe COVID-19 outcomes: Further understand impact of COVID-19 in high-risk population groups, especially in immunocompromised and elderly patients and in patients with multiple co-morbidities. 3. Long term outcomes of COVID-19: Studies assessing long-term or secondary consequences of the disease, including impact of reinfection and effects of different variants (includes but not exclusive to Long COVID/post-acute sequelae of SARS CoV-2 infection (PASC)) 4. Treatment of mild-to-moderate COVID-19 in vaccinated and or seropositive patients with nirmatrelvir/ritonavir 5. Impact of treatment for mild-to-moderate COVID-19 with nirmatrelvir/ritonavir on viral load, infectivity and/or transmission and/or viral rebound and/or symptom resolution 6. Regarding use of nirmatrelvir/ritonavir and showing outcomes: prescription behaviors (reason for non-prescription), patient refusal reasons, access and adherence to treatment Applicants are encouraged to collaborate across departments where appropriate (e.g., education, social services, health, etc.) and there is interest in seeing multi-country applications to allow for comparisons between countries on certain areas of interest. Requests for drug will be accepted. Commercial supply will be available only if approved in your country, not placebo matched drug. Individual projects requesting up to $200,000 USD will be considered. Pfizer anticipates awarding up to five grants. Letter of intent due November 17. Med-RA deadline to receive draft documents: November 3 due to Veterans Day holiday. Basic/Translational Research on Health Disparities in Underrepresented People Living with HIV (PLWH) and Cancer (Clinical Trial Not Allowed) R21 R01 Through these funding opportunity announcements, the National Cancer Institute intends to focus on the biological interactions of cancer health disparities in people living with HIV from underrepresented minority groups through basic mechanistic or translational studies to investigate how HIV interacts with health disparities to promote both non-AIDS and AIDS-defining cancer initiation, progression, and the resulting pathogenic disease sequelae. Due December 15, 2022 and December 15, 2023. Med-RA deadline to receive draft documents for 2022 due date: December 2. Intersection of Sex and Gender Influences on Health and Disease (R01 Clinical Trial Optional) The purpose of this Funding Opportunity Announcement (FOA) is to invite R01 applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 Trans-NIH Strategic Plan for Women's Health Research "Advancing Science for the Health of Women." The awards under this FOA will be administered by NIH ICs using funds that have been made available through the Office of Research on Women's Health (ORWH) and the scientific partnering Institutes and Centers across NIH. Due December 19, 2022; November 22, 2023; and November 22, 2024. Med-RA deadline to receive draft documents for 2022 due date: December 6. Walmart Community Foundation Grant Program There are eight (8) areas of funding for which an organization can apply. * Community and Economic Development: Improving local communities for the benefit of low-income individuals and families in the local service area * Diversity and Inclusion: Fostering the building of relationships and understanding among diverse groups in the local service area * Education: Providing afterschool enrichment, tutoring or vocational training for low-income individuals and families in the local service area * Environmental Sustainability: Preventing waste, increasing recycling, or supporting other programs that work to improve the environment in the local service area * Health and Human Service: Providing medical screening, treatment, social services, or shelters for low-income individuals and families in the local service area * Hunger Relief and Healthy Eating: Providing Federal or charitable meals/snacks for low-income individuals and families in the local service area * Public Safety: Supporting public safety programs through training programs or equipment in the local service area * Quality of Life: Improving access to recreation, arts or cultural experiences for low-income individuals and families in the local service area Local community grants range from a minimum of $250 to a maximum of $5,000. Note: This is a limited submission competition. FSU's internal deadline has passed, so submission to this competition is first come, first served. Visit the limited submission page to start the process. Sponsor deadline: December 31, 2022. Med-RA deadline to receive draft documents: December 7 due to Winter Break. Mechanism-Focused Research to Promote Adherence to Healthful Behaviors to Prevent Mild Cognitive Impairment (MCI) and Alzheimer's Disease (AD) and AD-Related Dementias (ADRD) (R61/R33 Clinical Trial Required) This Funding Opportunity Announcement (FOA) invites applications to address psychological and interpersonal mechanisms driving adherence to behaviors or lifestyle changes relevant to the prevention of cognitive decline, Mild Cognitive Impairment (MCI), and Alzheimer's disease (AD) and AD-related dementias (ADRD). Mechanisms of adherence may be studied in new, early- to late-stage (including Stages I-IV) behavior change trials. Applications should seek to identify malleable, mechanistic, psychological, or interpersonal targets that, if modified, will strengthen adherence to, maintenance of, and continued/renewed engagement in behaviors that may promote cognitive health and prevent AD/ADRD. This FOA utilizes the R61/R33 Exploratory/Developmental Phased Award activity code. The R61 phase will support pilot research to identify, measure, and assess the malleability of psychological or interpersonal adherence-relevant targets that, if successful, can transition to the R33 phase. The R33 phase will utilize results from the R61 phase to implement rigorous, proof-of-concept intervention studies. The transition from the R61 to the R33 phase will be administratively reviewed for, and be dependent upon, successful completion of the go/no-go criteria specified in the R61 phase. Due January 20, 2023. Med-RA deadline to receive draft documents: January 6 due to Martin Luther King Jr. holiday. Advancing Adolescent Tobacco Cessation Intervention Research R34 Clinical Trial Optional The purpose of this Funding Opportunity Announcement (FOA) is to provide support for research to facilitate well planned clinical trials aimed at advancing the science of tobacco cessation among adolescents. Specifically, the FOA invites applications for Planning Grants (R34) to inform the planning, design, and initial development of adolescent tobacco cessation behavioral intervention studies, with an emphasis on the critical developmental risk period ranging from mid- to late adolescence (i.e., approximately 14-20 years old). Applications should propose clinical trial planning activities that are scientifically necessary to guide the design and conduct of a future clinical trial evaluating a tobacco cessation behavioral intervention for adolescents. Planning activities could include, but are not limited to, feasibility and pilot studies to assess intervention viability and/or trial design, and testing of recruitment, retention, and adherence strategies to increase participant engagement and scientific rigor. R01 Clinical Trial Required The purpose of this Funding Opportunity Announcement (FOA) is to support studies that develop, test, implement, and evaluate behavioral tobacco cessation interventions for adolescents, with a focus on the critical developmental risk period of mid- to late adolescence (approximately 14-20 years old). Due January 23, 2023 and October 16, 2023. Med-RA deadline to receive draft documents for January 2023 due date: January 9 due to Martin Luther King Jr. holiday. AHEAD (Advancing Head and Neck Cancer Early Detection Research) (U01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to accelerate translation of research to improve early detection of head and neck cancers (HNC). This FOA seeks applications that focus on early detection of HNC by applying molecular, cellular, and multi-omics signatures to clinical studies for differentiating benign from premalignant lesions, and identifying prognostic signatures on the transformation from premalignant to malignant lesions. Better understanding of the molecular characteristics of dysplastic lesions and early recurrence are needed for improving lesion classification relevant to predicting cancer progression, which could have a significant impact on cancer prevention and treatment optimization. Due January 27, 2023. Med-RA deadline to receive draft documents: January 17. NLM Research Grants in Biomedical Informatics and Data Science (R01 Clinical Trial Optional) The National Library of Medicine (NLM) supports innovative research and development in biomedical informatics and data science. This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. The scope of NLM's interest in these research domains is broad, with emphasis on new and innovative methods and approaches to foster data driven discovery in the biomedical and clinical health sciences as well as domain-independent, scalable, and reusable/reproducible approaches to discovery, curation, analysis, organization, and management of health-related digital objects. Standard dates apply. Expires January 8, 2026. Med-RA deadline to receive draft documents for February 5, 2023 standard date: January 24. Utilizing Telomere Status to Reveal Molecular Mechanisms Underlying Susceptibility and Resiliency in Response to Environmental Exposures (R01 Clinical Trial Not Allowed) The purpose of this funding opportunity announcement (FOA) is to solicit applications that further examine and characterize molecular underpinnings surrounding telomere status and accompanying biological pathways in response to environmental insults. Specifically, the intent is to further stimulate the field on how general telomere maintenance modulates downstream biological pathway(s) leading to cellular and organismal dysfunction. It is anticipated that proposed studies examining exposure affects at telomeric regions can actually potentiate early onset of age-related diseases. This FOA ultimately seeks to identify key mechanistic insights into telomere dynamics and how this could better dissect the interplay between environmental exposures at this vulnerable site contribute to disease (e.g., cancer, cardiovascular disease, and other age-related outcomes, such as neurodegeneration). Due February 14, 2023. Med-RA deadline to receive draft documents: February 1. BRAIN Initiative: Brain-Behavior Quantification and Synchronization - Transformative and Integrative Models of Behavior at the Organismal Level (R34 Clinical Trial Not Allowed) This Funding Opportunity Announcement (FOA) seeks applications with limited scope proposing a set of planning activities that will lay the groundwork for a scientific project aimed at integrating complementary theories and methods to 1) develop, validate, and apply cutting-edge tools and methods for minimally invasive, multi-dimensional, high-resolution measurement of behavior at the level of the organism, with synchronous capture of changes in the organism's social or physical environment; and/or 2) develop computational methods that allow for integration of multidimensional behavioral and environmental data representing multiple timescales into a conceptual and/or computational model of behavior as a complex dynamic system, designed with the capacity to integrate synchronously recorded neural data and/or inform existing models of neurobehavioral function, such as those developed with the support of the NIH BRAIN Initiative. The purpose of this FOA is to support planning and development of the research framework, design, and approach, including activities that will establish feasibility, validity, and/or other technically qualifying results that, if successful, would support a competitive application for a U01, R01 or equivalent NIH research award. Due February 14, 2023. Med-RA deadline to receive draft documents: February 1. Immunity in Older Adults (U01 Clinical Trial Not Allowed) The purpose of this Funding Opportunity Announcement (FOA) is to support studies that provide mechanistic insights into innate and adaptive immune changes that occur during the aging process. The main objective of the program is to define the contribution of age-related alterations in different components of the immune system and the functional consequences in relation to infections, vaccine responses, and chronic inflammatory conditions. Due February 14, 2023. Med-RA deadline to receive draft documents: February 1. Biological Basis for how Environmental Exposures Impact Risk for Psychiatric Disorders (R21 / R01 Clinical Trial Not Allowed) R21 The objective of this funding opportunity announcement (FOA) is to solicit applications that propose to better understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence, or early adulthood. The R21 grant mechanism is intended to encourage exploratory and developmental research projects that are high-risk and/or use novel approaches with potential for significant impact. Investigations that further advance our understanding of psychiatric conditions where there is less evidence of an environmental exposure link are of particular interest. Since basic and pre-clinical research is critical for the study of neurobiological mechanisms that drive complex behaviors including mental illness, the focus of this FOA is to encourage a range of mechanistic approaches, from in vitro systems to whole organism models, to examine the link between environmental chemicals and possible contribution to the pathogenesis of psychiatric abnormalities. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are also welcomed. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. R01 The objective of this funding opportunity announcement (FOA) is to solicit applications that propose to better understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence, or early adulthood. Since basic and pre-clinical research is critical for the study of neurobiological mechanisms that drive complex behaviors including mental illness, the focus of this FOA is to encourage a range of mechanistic approaches, from in vitro systems to whole organism models, to examine the link between environmental chemicals and possible contribution to the pathogenesis of psychiatric abnormalities. Investigations that further advance our understanding of the joint contribution of genes and environment in the risk for psychiatric disorders are also welcomed. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. Due February 22, 2023. Med-RA deadline to receive draft documents: February 9. Avenir Award Program for Chemistry and Pharmacology of Substance Use Disorders (DP1- Clinical Trial Not Allowed) Avenir means future in French, and this Avenir Award Program looks toward the future by supporting early stage investigators proposing highly innovative research in the area of chemistry and pharmacology of substance use disorders and addiction. The purpose of this award is to support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field. Due August 9, 2023; August 9, 2024; and August 7, 2025. Med-RA deadline to receive draft documents for 2023 due date: July 27. Avenir Award Program for Genetics or Epigenetics of Substance Use Disorders (DP1 Clinical Trial Optional) Avenir means future in French, and this award looks toward the future by supporting early stage investigators proposing highly innovative studies. The award will support those in an early stage of their career who may lack the preliminary data required for an R01 grant, but who propose high impact research and who show promise of being tomorrow's leaders in the field of genetics or epigenetics of substance use disorders. The Genetics or Epigenetics of Substance Use Disorders Avenir Award program supports early stage investigators proposing highly innovative studies that open new areas of research for the genetics or epigenetics of addiction. These may be novel methods or approaches that can potentially be applied to the analysis of the genetics or epigenetics of addiction. Investigators outside the field of addiction interested in applying their novel approaches to the genetics or epigenetics of addiction are encouraged to apply. Due September 25, 2023; September 25, 2024; and September 25, 2025. Med-RA deadline to receive draft documents for 2023 due date: September 12. Contact Med-RA: research at med.fsu.edu -------------- next part -------------- An HTML attachment was scrubbed... URL: